American Shared Hospital Services (AMS) Earnings Call Transcript & Summary

November 12, 2020

NYSE American US Health Care Health Care Providers and Services earnings 21 min

Earnings Call Speaker Segments

Stephanie Prince

executive
#1

Thanks, Brandon, and I appreciate all of you being with us today. Prior to handing things off to management, I'd like to say a few words about forward-looking statements. Please be aware that certain comments that could be shared during this call regarding expectations, plans, and prospects for the company's future are forward-looking statements, made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Those forward-looking statements could point to results that differ materially from what actually occurs, owing to a number of significant factors, such as the ones addressed in the company's SEC filings. Among these are the annual report on Form 10 K covering the year that closed December 31, 2019, the Form 10 Q for the periods that ended March 31, 2020, and June 30, 2020, plus the definitive proxy statement for the shareholders' annual meeting held June 26, 2020. No duty is assumed by the company to refresh the information in this conference call. At this point, I'd like to pass the call to Ray Stachowiak, CEO of AMS. Ray?

Ray Stachowiak

executive
#2

Thank you, Stephanie. Good afternoon, everybody. We appreciate you being with us for this call covering our third quarter 2020 earnings. I'll start things off with a few comments, and after that Craig Tagawa, who serves as our President, COO and CFO, will walk through the business and operational results. Alexis Wallace, our Chief Accounting Officer, will follow with a financial review. After that, Craig, Alexis, Ernie Bates — our Senior Vice President, Sales and Business development and International Operations — and myself will take your questions. During the third quarter, our revenues recovered substantially compared with the low volumes we saw in the second quarter, during the toughest stretch of the COVID 19 pandemic. Craig will get into that in greater detail shortly. In September, the Board appointed me as CEO of AMS, which was a pleasure. At the same time, all of our corporate managers, many of whom you're familiar with, got well deserved promotions that better reflect their roles and responsibilities. I think we have an excellent team. Our shared objective is to achieve sustained profitability. There are three ways we can accomplish this by diversifying our business model: First, we can broaden our product offerings, so they cover not just proton beams and Gamma Knife, but MR Guided LINACs and more advanced LINACs as well. Second, we can grow geographically. A strong illustration of this is the acquisition we just completed of the sole Gamma Knife center located in Ecuador. Third, we can keep diversifying through the various methods by which we deliver our solutions; we can serve patients directly, as we do through our retail operations in Peru and Ecuador, or we can supply equipment and services on a wholesale basis, the way we do in the United States. I think AMS has plenty of opportunities for growth ahead, and with all the different ways we can satisfy their needs, we can offer enormous flexibility to the marketplace and our clients. I look forward to collaborating with the team to make that happen. I'll hand the call over to Craig now for a third quarter operational review. Craig?

Craig Tagawa

executive
#3

Thanks, Ray, and good afternoon to all of you. Like Ray said, our volumes came back strongly during Q3. Total revenue rose 17% on a sequential basis versus the second quarter, and it was also 2% above total revenue for the first quarter of 2020, before the pandemic. On a year over year basis, total revenue fell 11.9% compared with the third quarter of last year. Gamma Knife revenue likewise dropped 9.9% year over year, yet it rose 15.2% against the second quarter of 2020. The drop compared with a year ago came from two things: reduced average reimbursement at the company's retail locations, and a favorable contractual adjustment related to Medicare reimbursement at one of its sites that had been booked in last year's third quarter. For the third quarter of 2020, Gamma Knife procedures climbed 8.3% to 377, versus 348 in the same quarter the prior year, and they increased 7.7% from 350 in the second quarter of 2020. Volumes for Gamma Knife at centers and operations declined, along with reagents from Gamma Knife's revenue volumes at those centers in the comparable period a year before. Proton therapy was flat against the third quarter of 2019 and rose 20.4% over the second quarter of 2020. In Q3, proton therapy fractions overall increased 12.4% compared to the same period in 2019, and they rose 20.8% from Q2 2020. Gross margin during the third quarter dropped to 24.4% of revenue, down from 34.2% of revenue in Q3 2019, and it also slipped from the 20.7% of revenue recorded in Q2 2020. The net loss for Q3 totaled $209,000, whereas Q3 2019 saw net income of $165,000, and Q2 2020 had a net loss of $483,000. When comparing Q3 net income to the same period last year, the primary factor behind the decrease was reduced revenue from Gamma Knife. This resulted from a lower average reimbursement rate across the company's retail locations, in addition to legal expenses, other professional fees, and transaction costs tied to the June purchase of the Gamma Knife center in Ecuador, which totaled $69,000. We ended the quarter with a robust cash position totaling $3.6 million. In Q3, we completed the upgrade of the Gamma Knife Perfexion to the ICON platform at Lovelace Medical Center. A number of additional upgrades are still pending within our pipeline, including the Gamma Knife center Ecuador, which is set to be among just a handful in all of South America. Talks are ongoing with possible customers interested in the broader set of products we now offer, which Ray mentioned. As we look forward, given that COVID 19 infections are increasing globally, we are keeping a close watch for anything that might later affect how we run things; the RO APM that just came out did not include our Orlando Health PBRT center among those picked for the RO APM CMS announced. On top of that, we believe the RO APM will not have a substantial effect on what gets reimbursed for Gamma Knife procedures at 4 of our locations covered by the new <<inaudible>> model. We have also begun examining expenses carefully, especially when it comes to vendors, and we expect to roll out initiatives to save on selling and administrative costs at some point in 2021. So with that said, I'll hand things over now to Alexis, who will walk through the financials in detail. Alexis?

Alexis Wallace

executive
#4

Thanks, Craig, and good afternoon to all of you. Before I get into my prepared comments, I want to direct everyone to the earnings press release for our 2020 third quarter, which went out this morning. Should you require a copy, you can find it on our website, ashs.com, under the Investors tab in press releases. Now, on to our results for the third quarter. During the 3 months that ended September 30, 2020, total revenues fell 11.9% to $4.670 million, versus total revenue of $5.301 million in the third quarter of 2019, and rose 17% from total revenue of $3.991 million in the second quarter of 2020. No revenue was recorded by the company from its IGRT equipment this quarter, compared with $314,000 in the third quarter of 2019. That equipment was fully depreciated and was sold in July following expiration of the company's contract. For the Proton therapy system the company has installed at Orlando Health in Florida, third quarter revenue grew 0.6% to $1.687 million, versus revenue of $1.677 million in the third quarter of 2019, and grew 20.4% from revenue of $1.401 million in the second quarter of 2020. Higher volumes drove the year over year increase, though a lower average reimbursement for fraction partly offset it. Average reimbursement for fraction matched what we saw in the second quarter of 2020. Total proton therapy fractions came to 1,632 in the third quarter, up 12.4% from 1,452 proton therapy fractions in the third quarter of 2019, and up 20.8 from 1,351 in the second quarter of 2020. At the company's Gamma Knife operations, revenue declined 9.9% to $2.983 million in the third quarter of 2020, versus $3.310 million in the third quarter of 2019, and rose 15.2% from $2.59 million in the second quarter of 2020. Lower average reimbursement at the company's retail sites, plus a positive contractual adjustment tied to Medicare reimbursement at one of the company's sites that was recognized in the prior year's third quarter, drove the year over year decline. Gamma Knife's procedures rose by 8.3% to $377 in the third quarter of 2020 from $348 in the same period of the prior year, and 7.7% from $350 in the second quarter of 2020. The increase from the second quarter reflects the acquisition of Gamma Knife center Ecuador. Gamma Knife volumes for centers and operations fell 8% from Gamma Knife volumes for the same centers during the same period of the prior year. Gross margin for the third quarter of 2020 fell to $1.138 million, or 24.4% of revenue, versus gross margin of $1.830 million, or 34.2% of revenue, for the third quarter of 2019, and rose from $907,000, or 22.7% of revenue, for the second quarter of 2020. Selling and administrative costs rose by $70,000, or 6.6%, to $1.135 million for the third quarter, versus $1.065 million for the third quarter of 2019, and declined 6.2% from $1.210 million for the second quarter of 2020. Compared to a year ago, the rise comes from $69,000 in tax, legal, and consulting costs tied to the company's purchase of GK <<inaudible>>. For the third quarter of 2020, we recorded a net loss of $209,000, or $0.03 per diluted share. That's against net income of $165,000, or $0.03 per diluted share, in the third quarter of 2019, and a net loss of $483,000, or $0.08 per diluted share, in the second quarter of 2020. Weighted average common shares outstanding, fully diluted, came to 6.049 million and 5.908 million in the third quarters of 2020 and 2019, respectively. Adjusted EBITDA, which is a non GAAP financial measure, reached $1.979 million in the third quarter of 2020, versus $2.445 million in the third quarter of 2019 and $1.437 million in the second quarter of 2020. The main driver of the decrease from a year ago was lower overall income. Now let's look at the balance sheet. Cash, cash equivalents and restricted cash stood at $3.983 million on September 30, 2020, up from $1.779 million on December 31, 2019. That wraps up the formal portion of our presentation. Brandon, at this point we'd like to hand the call back to you for questions.

Leonard Dunn

analyst
#5

Results for the period were uneven, driven by unusual expenses. And clearly, nobody can predict the duration of this latest COVID surge, though it appears the vaccine is here. And we definitely now possess a greater capacity to keep things under control. So my rough estimate would be that once we finish the opening calendar quarter of the coming year, it will remain an issue, yet not a significant one the way it is today. Are you encountering any difficulty persuading individuals to visit a hospital for procedures at this moment?

Ray Stachowiak

executive
#6

Craig, do you want to handle that? Absolutely. Lenny, it truly varies by geography, in terms of whether patients are completely returning at this point. So it's and given the present surge in COVID 19, it will be tough to determine whether a disruption will persist as we move forward. But as you mentioned, with encouraging vaccines being released, we ought to see some relief from that likely at some point in the middle to later portion of 2021, I would guess.

Leonard Dunn

analyst
#7

All right. Yet isn't it true that individuals receiving Gamma Knife therapy genuinely require those procedures? Therefore, if they put them off temporarily, most likely they would not wish to delay them with no end in sight, since what is left as an option isn't favorable.

Craig Tagawa

executive
#8

Correct. For those with metastatic brain tumors, I believe that holds true. Those who have benign tumors or trigeminal neuralgia might opt to wait for some duration. However, like you mentioned, they cannot put it off permanently. If they did, they would no longer qualify for Gamma Knife treatment, as their tumors could grow too big.

Leonard Dunn

analyst
#9

All right. So I suppose there’s a sort of equilibrium at play here, likely stemming from those delays that happened earlier in the year. If folks fall into that group, it would counterbalance a portion of the newer individuals who ought to be doing well. So the situation could improve. But how much lead time is required for someone to reserve them?

Craig Tagawa

executive
#10

The lead time isn’t very long; the main thing is getting in to see their doctors, having those doctors look over their MRIs and confirm that it is, once again, an indication that can be treated with the knife. So it simply comes down to getting in to their doctors and then being scheduled for the Gamma knife treatment.

Leonard Dunn

analyst
#11

All right. My next question concerns the fact that we've been waiting quite a while for another proton center to get underway, and I'm certain your view matches mine on that. Can we see any light at the end of the tunnel there?

Ray Stachowiak

executive
#12

Lenny, I appreciate the question. Bolt-on opportunities are still something we're chasing. That said, as we've said before, sales cycles for these items run very long. Those opportunities remain something we keep pursuing, yet our feeling is that the smartest path for this company involves not putting every egg into a single basket, if you will; and when it comes to delivering radiation treatment to cancer patients, we hold a unique position to offer additional products; many different products exist, for example an MR guided LINAC, which we can also bring to the marketplace, and that aligns with our broader mission of providing these therapies, in treatments. As you're aware, and as we may have said before, a Gamma Knife carries a lower cost structure than the MR Guided LINAC, while a proton beam system costs significantly more than the MR Guided LINAC.

Leonard Dunn

analyst
#13

Right, I get it — having multiple revenue channels is a positive thing. When it comes to deals of that kind, are we anywhere near getting some signed?

Ray Stachowiak

executive
#14

That's tough to predict. What I can tell you is that during this third quarter, we've seen a greater amount of sales activity. Compared with the first and second quarters of this year, things have definitely gotten busier on the sales front, so to me, that looks like an encouraging signal.

Ray Stachowiak

executive
#15

Okay, thanks to all of you for being here with us today. If anything comes up before Q4 wraps and ahead of our call to discuss the close of 2020 in the middle of March, please reach out to us straight away. Take care of yourselves, they say, and I hope your day is a good one. Bye now.

Operator

operator
#16

Appreciate it. That wraps up the call for today, everyone. Thanks for being with us. You're free to hang up now.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete American Shared Hospital Services transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

For developers and AI pipelines

Programmatic access to American Shared Hospital Services earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in American Shared Hospital Services or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.